Marina Biotech, Inc. to Present Clinical Data from its CEQ508 Phase 1 Trial for the Treatment of Familial Adenomatous Polyposis
January 09, 2017 at 07:58 pm IST
Share
On January 9, 2017, Marina Biotech, Inc. will present clinical data from its CEQ508 phase 1 trial for the treatment of Familial Adenomatous Polyposis (FAP) at its previously announced presentation at the 9 Annual Biotech Showcase. The trial has met its primary and secondary endpoints of safety and efficacy for CEQ508. Management will also state during the presentation its intentions to continue clinical development of CEQ508 in combination with IT-102, which was acquired in the recent merger with IthenaPharma.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.
ADHERA THERAPEUTICS, INC. 
